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compare atherectomyballoon angioplasty ('Non-stent') and stenting ('Stent')
outcomes for superﬁcial femoral artery (SFA), popliteal and below-the knee (BTK)
revascularization.
Results: A total of 413 interventions (SFA¼79.2%; popliteal¼9.2%; BTK¼11.5%)
were performed in 254 patients (Rutherford category 3¼81.7%; 4-5¼14.1%). Stents
were deployed in 60.8% of lesions (SFA¼ 92.4%; popliteal¼3.8%; BTK¼3.8%) and
non-stent strategy (atherectomy in 44.3%) used in 39.1% (SFA¼58.8%; pop-
liteal¼17.6%; BTK¼23.5%). In the 'Stent' and 'Non-stent' groups, mean lesion length
were 136.9 mm and 77.6 mm, respectively (p<0.001), with more interventions for
critical limb ischemia (CLI; p¼0.006) in the 'Non-stent' group. Chronic total
occlusions constituted 62.2% of 'Stent' and 38.0% of 'Non-stent' treated lesions
(p<0.001). At a median follow-up of 210 days (IQR¼120-330), all-cause mortality
was 5.3% in the 'Stent' and 4.6% in the 'Non-stent' treated patients (p¼0.79); repeat
revascularization (RR) was required in 19.0% 'Stent' and 17.8% 'Non-stent' patients
(p¼0.78) and amputation in 3.8% in 'Stent' and 9.3% 'Non-stent' patients (p¼0.003;
Figure 1).Characteristic % (Na)
History of smoking 84% (210/251)
Current diabetes mellitus 41% (104/251)
History of hyperlipidemia 75% (188/251)
History of hypertension 82% (205/251)
History of coronary artery disease 44% (110/251)
History of myocardial infarction 25% (63/251)
History of chronic heart failure 8% (21/251)
History of renal insufﬁciency 10% (24/251)
History of peripheral vascular surgery 10% (24/251)
History of other peripheral endovascular interventions 42% (106/251)
a8 patients did not have clinical history information available.
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dicants compared to a 'Non-stent' strategy for BTK interventions in CLI, with similar
need for RR and lower amputations in the 'Stent' group.
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Drug-Eluting Stents Below The Knee - Promises And Limitations: Update On
The DESTINY And ACHILLES Trials Comparing DE To Bare Metal Stents
Koen Keirse1
1Heilig Hart Hospital, Tienen, Belgium
Background: The ACHILLES study is a prospective, randomized, multi-center
comparison of balloon angioplasty and the Cypher SelectTM+ coronary and
infrapopliteal stent in the treatment of subjects with ischemic infrapopliteal arterial
disease. In total 200 subjects were included, according to a 1:1 randomization sche-
me. Patients were eligible for inclusion when presenting with clinical symptoms
according to Rutherford categories 3, 4 or 5 and presenting with de novo or restenosis
post-PTA lesions in the infrapopliteal vasculature. A maximum of 4 stents were
allowed to be implanted in maximally two lesions, with a lesion length of up to
90mm. Primary endpoint of ACHILLES is absence of in-segment binary restenosis
after 12 months, deﬁned as absence of binary restenosis (>50%) in and/or 5mm
proximal and/or 5mm distal to the treated segment as determined by quantita-
tive angiography (QA). Inclusion was ﬁnished in January 2010, no results are avail-
able yet.
Methods: Simultaneously, the 12-months results from another BTK-study, the
Drug Eluting Stents in the Critically Ischemic Lower Leg (DESTINY) study, are
being collected. This prospective, randomized, multi-center trial compares outcome
with the implant of the Abbott Vascular Xience V drug-eluting stent (DES) versus
the Abbott Vascular MultiLink Vision bare-metal stent (BMS) for treatment of
infrapopliteal arterial lesions of maximally 40mm long in patients with critical
limb ischemia (CLI). Patients eligible for inclusion had clinical symptoms
according to Rutherford categories 4 or 5 and presented with maximum of 2 below-
the-knee stenoses (50%) or occlusions is allowed, corresponding with a maximum
of 2 stents to be implanted. Primary endpoint of DESTINY is primary patency
after 12 months, deﬁned as 12-month angiographic binary in-stent restenosis
rate (>50% stenosis). Quantitative Vascular Analysis is performed, comparing
biplanar digital subtraction angiographic images immediately post-operatively and at
the 12 month follow-up control visit. Binary restenosis rate for DES and BMS at 12
months is compared using a Pearson Chi-square test, performed at the 5% signiﬁ-
cance level.
Results and Conclusions: Will be presented at TCT 2013.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-525
SuperNOVA Trial Design and Demographic Data: Stenting of the Superﬁcial
Femoral and Proximal Popliteal Arteries with the InnovaTM Self-Expanding
Bare Metal Stent System
Richard Powell1, Stefan Müller-Hülsbeck2, Robert Bersin3, Herman Schroe4,
Andrew Benko5, Juan Diaz-Cartelle6
1Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Ev. Luth. Diakonissenanstalt
Flensburg, Flensburg, Germany, 3Swedish Medical Center, Seattle, Washington,
4Ziekenhuis Oost-Limburg, Genk, Belgium, 5Centre Hospitalier Universitaire de
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Background: Lower limb ischemia due to atherosclerosis is associated with symp-
toms ranging from mild claudication to tissue loss. The purpose of the SuperNOVA
clinical study was to evaluate the safety and efﬁcacy of the investigational Innova
Self-Expanding Stent System (Boston Scientiﬁc Corporation, Natick, MA, USA) in
patients needing treatment of lesions in their femoropopliteal arteries.
Methods: The SuperNOVA study was a prospective, single arm, core lab-controlled,
multicenter, global clinical trial. Approximately 55 centers located in the United
States, Europe, Canada, and Japan enrolled up to 300 subjects. Eligibility for the study
included age >18 years with chronic lower limb ischemia deﬁned as Rutherford
categories 2, 3, or 4, and stenotic, restenotic (from angioplasty only), or occlusive
lesions located in the native superﬁcial femoral artery or proximal popliteal artery.
Target vessel diameter was 4 and 7 mm with stenosis at least 70% by visual
angiographic assessment, and total lesion length 30 mm and 190 mm. Following
device implantation, follow-up visits were scheduled at 1, 6, and 12 months. The
primary safety endpoint was occurrence of Major Adverse Events (i.e., all-cause death
through 1 month, target limb major amputation through 12 months, and target lesion
revascularization through 12 months). The primary efﬁcacy endpoint was vessel
primary patency at 12 months. Restenosis was deﬁned as duplex ultrasound systolic
velocity ratio >2.4.
Results: As of June 3, 2013, 259 patients were enrolled; 9.6% were 1 year post-
procedure. Mean age of the patients was 67.2 (SD 9.6) years and 74% were male; 82%
were Caucasian and 12% were Asian. Baseline clinical characteristics are shown in the
Table. Long stents (180-200 mm) were used by 40 patients.Conclusions: The SuperNOVA clinical investigation is ongoing. Enrollment is ex-
pected to be complete by June 2013.
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A New Scoring System for Predicting Wound Healing in Critical Limb Ischemia
with Tissue Loss following Endovascular Therapy
Norihiro Kobayashi1, Toshiya Muramatsu1, Reiko Tsukahara1, Yoshiaki Ito1,
Hiroshi Ishimori1, Keisuke Hirano1, Masatsugu Nakano1
1Saiseikai Yokohama-city Eastern Hospital, Yokohama, Japan
Background: Wound healing is very important endpoint in critical limb ischemia
(CLI) with tissue loss. The aim of this study was to design a scoring system for
predicting wound healing in CLI patients who were treated with endovascular therapy
(EVT) in consideration of various factors including patient background, intervention
outcomes, and also wound characteristics.
Methods: Between April 2007 and October 2012, 184 patients (217 limbs) were
treated with EVT for CLI with tissue loss in our institute. In these limbs, 236 indi-
vidual wounds existed and were divided into a development group (n¼118) and
a validation group (n¼118). Each variables which seem to be associated with wound
healing were analyzed using the univariate Cox proportional hazards model. All
variables tested in univariate analysis with p<0.25 were included in multivariate Cox
hazards model. The scores for each variables were transformed from regression
coefﬁcients and computed in a total score.acts/POSTER/Endovascular Intervention B159
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wounds (HR 0.38, 95%CI 0.16-0.93, p¼0.034), dependence on hemodialysis (HR
0.46, 95%CI 0.27-0.80, p¼0.006), infectious wound (HR 0.54, 95%CI 0.30-0.99,
p¼0.044), heel wound (HR 0.38, 95%CI 0.16-0.91, p¼0.029) and extensive wound
extending onto the forefoot or midfoot along the dorsal or plantar surfaces (HR 0.09,
95%CI 0.02-0.39, p¼0.001) were adverse predictors of wound healing. Each item's
score ranged from 0 to 4 and the total score ranged from 0 to 10. The area under the
receiver operating characteristics curve revealed that there was 90.5% accuracy in the
total scores predicting the likelihood of wound healing. In the development group, the
wound healing rates at 12 months were 83% in low-risk group (scores&2), 33% in
moderate-risk group (scores 3-5), and 4.0% in high-risk group (scoresS6) (p<0.001).
In the validation group, the corresponding wound healing rates were 80%, 49%, and
12%, respectively (p<0.001).
Conclusions: This new scoring system is useful for the risk stratiﬁcation of wound
healing in patients with CLI.
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What are the Predictors of Wound Healing in Patients with Critical Limb
Ischemia with Tissue Loss following Successful Endovascular Therapy?
Norihiro Kobayashi1, Toshiya Muramatsu1, Reiko Tsukahara1, Yoshiaki Ito1,
Hiroshi Ishimori1, Keisuke Hirano1, Masatsugu Nakano1
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Background: Sometimes we can't achieve wound healing in patients with critical
limb ischemia (CLI) with tissue loss even after successful endovascular therapy
(EVT). Multiple factors including patient background, intervention outcomes, and also
wound characteristics are associated with wound healing. Therefore we evaluated
predictors of wound healing in CLI after successful EVT.
Methods: Between April 2007 and April 2012, 179 patients (217 limbs) with CLI
classiﬁed to Rutherford 5 or 6 were treated with EVT in our institute. Of these, 128
patients (146 limbs) were successfully treated. Successful EVT was deﬁned as
revascularization of achievement of direct blood ﬂow to the wounds evaluated by
digital subtraction angiography just after EVT. Each variables were analyzed using the
univariate Cox proportional hazards model for wound healing. All variables tested in
univariate analysis with p < 0.25 were included in multivariate Cox hazards model.
Results: The mean follow-up period was 2117 months. Wound healing rates were
41%, 58%, 71%, and 72%, at 3, 6, 12, and 18 months, respectively. Multivariate Cox
proportional hazard analysis revealed that insulin use (HR 0.47, 95%CI 0.30-0.73,
p¼0.001), dependence on hemodialysis (HR 0.35, 95%CI 0.23-0.53, p<0.001),
wounds located only at toes (HR 2.79, 95%CI 1.78-4.38, p<0.001), gangrene (HR
0.66, 95%CI 0.44-0.97, p¼0.037), and revascularization basing on angiosome concept
(HR 1.53, 95%CI 1.16-2.02, p¼0.002) were independent predictors of wound healing
following successful EVT.
Conclusions: Achievement of direct blood ﬂow to the wounds is important factor for
wound healing, but that is not enough. Insulin use, dependence on hemodialysis, and
gangrene can be predictors of wound healing failure. Furthermore, wounds located
only at toes and revascularization basing on angiosome concept can be predictors of
wound healing.
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Background: The clinical efﬁcacy of infrapopliteal balloon angioplasty for hemo-
dialysis patients with critical limb ischemia has not been systematically studied.
Methods: This study consisted of multi-center retrospective study. Subjects were
1093 CLI patients with 1314 limbs who underwent balloon angioplasty as primary
treatment of isolated infrapopliteal lesions from 2004 to 2012. Subjects were classiﬁed
into two groups for non-randomized comparative study: the patients on chronic
hemodialysis: HD group (671 patients, 833 limbs, age: 69  10 years) and without
HD: No-HD group (422 patients, 481 limbs, age: 76  10 years). Clinical outcome
between two groups were examined with average for 4.01.2 year. Outcome
measures were freedom from major amputation (MA), major adverse limb events with
perioperative death (MALE+POD) and amputation-free survival (AFS) at 1 and 5
years estimated using the Kaplan-Meier methods.
Results: For patient characteristics, the rate of diabetic patient was similar (73.1 vs.
69.4%, P¼0.691) in both groups. The percentage of CLI with Rutherford category 5
or 6 (80.2 vs. 70.9%, P<0.01) and No-ambulance status (42.8 vs. 34.6%, P<0.01) was
signiﬁcantly higher in HD group than that of Non-HD group. For the target vessel,
there was no signiﬁcant difference in the rate of patent dorsal and planter artery ﬂow
after balloon angioplasty (48.9 vs. 50.9%). Complete healing rate of CLI wounds
(56.3 vs. 69.1%, P<0.01) was signiﬁcantly lower in HD group than that of Non-HD
group. Regarding clinical results, The HD group had a signiﬁcantly lower freedom
from MA (86.01.5 vs. 90.61.5% at 1 year, 81.52.6 vs. 88.91.7% at 5 year,
P¼0.033.), MALE+POD (77.91.7 vs. 85.31.8% at 1 year, 69.43.2 vs.B160 JACC Vol 62/18/Suppl B j October 27–N81.72.3% at 5 year, P<0.001.) and AFS (64.82.0 vs. 77.92.1% at 1 year,
32.03.0 vs. 59.93.3% at 5 year, P<0.001.) compared to Non-HD group. The AFS
rate at 1 year in HD group was below the 71% suggested objective performance goal
in catheter based therapies.
Conclusions: The clinical efﬁcacy of infrapopliteal balloon angioplasty for hemodi-
alysis patients with critical limb ischemia was not satisfactory because patients on
hemodialysis had high mortality rates.
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Comprehensive Assessment of Prevalence and Distribution of Obstructive Pelvic
Arterial Lesions by Computed Tomographic Angiography in Patients with
Erectile Dysfunction
Tzung-Dau Wang1, Wen-Jeng Lee1, Wen-Jone Chen1, Ming-Fong Chen1
1National Taiwan University Hospital, Taipei City, Taiwan, Republic of China
Background: Recent studies showed that endovascular intervention of focal athero-
sclerotic lesions of the internal pudendal arteries can result in improvement of erectile
function. However, studies regarding the prevalence and distribution of obstructive
pelvic arterial lesions amenable to endovascular therapies are scarce.
Methods: This study included 80 consecutive patients (mean age 62.6 years) with
erectile dysfunction underwent multi-detector computed tomography (CT). Pelvic CT
angiograms of the arterial system supplying the penis were divided into 5 segments:
common iliac artery, internal iliac artery, anterior division, internal pudendal artery,
and penile artery. Obstructive arterial lesion was deﬁned by a luminal stenosis of
50% on CT.
Results: Among the 800 segments obtained, only 4 segments (0.5%) of penile arteries
were identiﬁed as non-analyzable. 67 patients (67/80, 84%) had at least one
obstructive lesion in their pelvic CT angiograms. A total of 157 obstructive segmental
lesions were identiﬁed. The distribution of these obstructive pelvic arterial lesions
was: 1 (0.01%) in common iliac artery segment, 4 (2.5%) in internal iliac artery
segment, 13 (8.3%) in anterior division segment, 68 (43%) in internal pudendal artery
segment, and 71 (45%) in penile artery segment. Bilateral obstructive lesions were
present in 37 patients. The obstructive lesions were limited in penile artery segments
in 18 patients (18/67, 27%), whereas only 9 patients (13%) with obstructive lesions
limited in the internal pudendal artery segments. Fifteen patients (19%) had accessory
penile blood supply.
Conclusions: Obstructive pelvic arterial lesions were highly prevalent in patients with
erectile dysfunction. These obstructive lesions were most frequently present in the
penile artery segment, followed by in the internal pudendal artery segment. Almost
30% of patients got their obstructive lesions limited in the penile artery segments.
These ﬁndings not only demonstrate the feasibility of CT angiography as a diagnostic
tool for patients with erectile dysfunction, but also suggest that the focus of inter-
ventional strategy should include penile arteries, rather than solely on internal
pudendal arteries.
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Long-term Cost Patterns of Directional Atherectomy vs. Other Treatment
Choices for Diabetes Patients with Peripheral Artery Disease: a 12-Month
Analysis of Administrative Claims Data
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1Emory University, Alpharetta, GA, 2HealthCore Inc, Wilmington, DE, 3Covidien,
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Background: Directional atherectomy is an endovascular therapy that is effective in
the treatment of diabetes patients with peripheral artery disease (PAD). This study was
undertaken to assess the prevalence of PAD treatments in a real-world diabetic pop-
ulation, and to compare all-cause healthcare costs of directional atherectomy with
other therapies in diabetes patients over 12-months post-treatment.
Methods: PAD patients were selected from a large claims database with 1 CPT code
for a lower extremity PAD procedure between 2005-2011. The date of the ﬁrst CPT
code was the index date. Patients were included with: 12-months of pre-index date
continuous medical and pharmacy eligibility; 1 PAD ICD-9 code within 6 months
prior to the index date; 1 medical claim for Type 2 Diabetes Mellitus during
baseline; and 18 years of age on index date. Multivariate models to evaluate risk of
hospitalization during follow-up and all-cause health care cost at 12 months were
constructed, controlling for covariates.
Results: 8,121 Patients had both diabetes and PAD, with a mean age of 67.6 years and
39% were female. Prevalence of PAD treatment was: stent(26%), bypass(23%),
PTA+stent(22%), PTA(16%), PTA+atherectomy(4%), atherectomy(4%), unspeci-
ﬁed(4%), and PTA+stent+atherectomy(1%). At 12-months post-procedure(N¼5,660),
the atherectomy group had the lowest mean healthcare costs ($34,754) and bypass had
the highest ($45,181). There were no statistically signiﬁcant differences between
atherectomy and any of the treatments with respect to all-cause health care costs over
12 months, though the cost for atherectomy was lowest. Bypass patients were 33%
more likely to be hospitalized during follow-up than atherectomy patients, but athe-
rectomy patients were not statistically signiﬁcantly different from any other therapies.
Conclusions: Because diabetics tend to re-stenose faster and are more complex than
non-diabetic PAD patients, atherectomy is a good therapeutic choice, as it preserves
future treatment options. Among PAD patients with diabetes in this large claims
database, directional atherectomy was associated with similar re-hospitalization rates
and similar or lower costs compared to other PAD therapies over 12 months.ovember 1, 2013 j TCT Abstracts/POSTER/Endovascular Intervention
